Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Institut Regional du Cancer de Montpellier-Val d'Aurelle, Universite De Montpellier 1, Oribase Pharma
InventorsBruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
Estimating the term…
The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
A monoclonal antibody or an antigen binding fragment thereof, wherein said monoclonal antibody or antigen binding fragment thereof has specificity for Axl and comprises an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region;
A method for diagnosis of cancer, comprising using an antibody or an antigen binding fragment thereof for the diagnostic method.
Dependencies are inferred from the claim text.